CD274 and non-small cell lung carcinoma: Currently, drugs that target PD-1 have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for malignant melanoma and non-small cell lung cancer (NSCLC), and there are currently ongoing trials for drugs targeting PD-L1 [9, 10].